Elevation Oncology – Antibody Drug Conjugate

Joe Ferra, Interim CEO and CFO of Elevation Oncology discusses the company’s development of an antibody-drug conjugate (ADC) that targets Claudin18.2, a therapeutic target in the oncology field. The company’s Chinese partner released data on the company’s lead asset at ASCO 2023, which demonstrated safety and early signs of efficacy in patients with resistant/refractory solid tumors. He also talks about Elevation’s other therapeutic candidates.

Joseph Ferra brings to Elevation over 20 years of financial, strategic and leadership experience in the pharmaceutical/biotechnology industry. Prior to joining Elevation, he was Chief Financial Officer of Syros Pharmaceuticals where he led the development and implementation of key financial and capital strategies and contributed to corporate initiatives. Previously, he spent over a decade as an investment banker in the biotechnology and pharmaceutical industry, where he established a strong track record of advising on equity and M&A transactions. This included serving as Managing Director and Co-Head of Healthcare Investment Banking at JMP Securities and being a member of the investment banking groups at JP Morgan and UBS. Earlier in his career, Joe served in sales and engineering roles in the life science tools industry. He earned his MBA from The Stephen M. Ross School of Business at the University of Michigan. He obtained a B.S. in Chemistry with Distinction from Purdue University, where he contributed to published papers and conducted research at the National Institutes of Health.

Joe also currently serves as a member of the Executive Committee of the General Board of Directors and as the Chair of Audit & Risk Committee for the YMCA of Greater Boston.

Joe resides in Rhode Island and enjoys playing guitar, sailing, hiking and anything else involving the outdoors.